統合失調症治療薬の世界市場レポート 2025年

統合失調症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.3％で、108億5,000万米ドルに成長します。予測期間中に予想される成長は、より効果的な治療結果に対する需要の増加、抗精神病薬の進歩に焦点を当てた研究開発活動の活発化、製品の上市、規制当局の承認、精神疾患のための新薬開発への投資の増加などの要因によるものです。その他の寄与要因としては、メンタルヘルス治療に対する保険適用の向上、政府の取り組み、支援などが挙げられます。この期間に予想される主な動向としては、長時間作用型注射製剤の開発、モバイルアプリやウェアラブルなどのデジタルツールの導入、グルタミン酸作動性経路を標的とする薬剤の出現、遺伝子研究やバイオマーカー研究の活用、補助療法への注目の高まりなどが挙げられます。

統合失調症患者数の増加が統合失調症治療薬市場の成長を牽引すると予想されます。統合失調症は、歪んだ思考、知覚、感情、行動を特徴とする慢性の精神疾患であり、しばしば幻覚や妄想を引き起こします。遺伝的素因、環境的ストレス要因、薬物乱用、脳内化学物質の不均衡などが統合失調症患者の増加に寄与しています。統合失調症治療薬は症状の管理に役立ち、患者の日常生活への影響を軽減し、全体的な治療成績を向上させる。例えば、2024年2月、米国の生物医学図書館である国立医学図書館は、米国人口における統合失調症および関連する精神病性障害の有病率は0.25％から0.64％であると報告しました。さらに2024年1月、カナダに本部を置く非営利団体であるブリティッシュ・コロンビア統合失調症協会は、統合失調症は精神疾患による入院の主な原因であり、一般病院入院の19.9％、精神科病院入院の30.9％を占めると発表しました。その結果、統合失調症患者数の増加が統合失調症治療薬市場の成長を促進します。

統合失調症治療薬市場の主要企業は、患者のケアと治療成績を向上させるため、統合失調症向け経口薬などの先進治療法の開発に注力しています。統合失調症の経口薬は、統合失調症の症状を管理するために口から服用するもので、一般的には気分や思考、知覚を安定させる抗精神病薬が用いられます。例えば、2024年9月、米国のバイオ医薬品会社であるブリストル・マイヤーズスクイブ社は、成人の統合失調症治療用の革新的な経口薬であるコーベンファイが米国食品医薬品局（FDA）より承認されたと発表しました。この画期的な薬剤は、キサノメリンと塩化トロスピウムを組み合わせたもので、ドーパミン受容体ではなくコリン作動性受容体を標的とすることで、従来の抗精神病薬とは異なる新しいアプローチを提供します。このユニークなメカニズムにより、従来の抗精神病薬に伴う一般的な副作用を最小限に抑えながら、妄想や思考の混乱などの症状を緩和する可能性があり、コーベンフィーは統合失調症治療の有望な選択肢となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界統合失調症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の統合失調症治療薬市場：成長率分析
• 世界の統合失調症治療薬市場の実績：規模と成長, 2019-2024
• 世界の統合失調症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界統合失調症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の統合失調症治療薬市場治療クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第二世代
• 第三世代
• その他の治療クラス
• 世界の統合失調症治療薬市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 世界の統合失調症治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の統合失調症治療薬市場、第2世代のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リスペリドン
• オランザピン
• クエチアピン
• アリピプラゾール
• パリペリドン
• ジプラシドン
• その他
• 世界の統合失調症治療薬市場、第3世代のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブレクスピプラゾール
• カリプラジン
• その他
• 世界の統合失調症治療薬市場、その他の治療クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一世代抗精神病薬
• 併用療法
• その他

第7章 地域別・国別分析

• 世界の統合失調症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の統合失調症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 統合失調症治療薬市場：競合情勢
• 統合失調症治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol Myers Squibb
• AstraZeneca PLC
• Eli Lilly and Company
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.
• Sun Pharmaceutical Industries Ltd.
• AbbVie Inc.
• H. Lundbeck A/S
• Cipla Ltd.
• Lupin Limited
• Alkermes plc
• Vanda Pharmaceuticals Inc.
• Sumitomo Pharma Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 統合失調症治療薬市場2029：新たな機会を提供する国
• 統合失調症治療薬市場2029：新たな機会を提供するセグメント
• 統合失調症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Schizophrenia medications are designed to alleviate the symptoms of schizophrenia, a chronic mental disorder that impacts thoughts, perceptions, emotions, and social interactions. These drugs work by addressing chemical imbalances in the brain, particularly those involving dopamine and serotonin, which helps reduce psychotic symptoms, stabilize mood, and improve cognitive abilities, leading to better daily functioning and increased independence.

The primary therapeutic categories of schizophrenia drugs include second-generation, third-generation, and other types. Second-generation antipsychotics, also known as "atypical" antipsychotics, treat schizophrenia by targeting dopamine and serotonin receptors. These drugs provide symptom relief with a reduced risk of movement disorders compared to first-generation antipsychotics. They are available in various forms, such as oral and injectable, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets.

The schizophrenia drugs market research report is one of a series of new reports from The Business Research Company that provides schizophrenia drugs market statistics, including the schizophrenia drugs industry global market size, regional shares, competitors with the schizophrenia drugs market share, detailed schizophrenia drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the schizophrenia drugs industry. These schizophrenia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The schizophrenia drugs market size has grown strongly in recent years. It will grow from $7.96 billion in 2024 to $8.49 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth during the historic period can be attributed to several factors, including the introduction of newer drugs such as second- and third-generation antipsychotics, an increase in the prevalence of mental health disorders and schizophrenia, heightened awareness about mental health, a rise in mental health awareness programs by both government and non-government organizations, and a growing geriatric population.

The schizophrenia drugs market size is expected to see strong growth in the next few years. It will grow to $10.85 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth anticipated during the forecast period can be attributed to factors such as the increasing demand for more effective treatment outcomes, a rise in research and development activities focused on advancements in antipsychotic drugs, product launches, and regulatory approvals, as well as growing investments in the development of new pharmaceuticals for mental health conditions. Other contributing factors include better insurance coverage for mental health treatments, government initiatives, and support. Key trends expected during this period include the development of long-acting injectable formulations, the introduction of digital tools such as mobile apps and wearables, the emergence of drugs targeting glutamatergic pathways, the use of genetic and biomarker research, and an increasing focus on adjunct therapies.

The increasing number of schizophrenia cases is expected to drive the growth of the schizophrenia drugs market. Schizophrenia is a chronic mental disorder characterized by distorted thoughts, perceptions, emotions, and behaviors, often leading to hallucinations and delusions. Factors such as genetic predisposition, environmental stressors, substance abuse, and imbalances in brain chemistry are contributing to the rise in schizophrenia cases. Schizophrenia medications help manage symptoms, reducing the disorder's impact on patients' daily lives and improving overall treatment outcomes. For example, in February 2024, the National Library of Medicine, a US-based biomedical library, reported that the prevalence of schizophrenia and related psychotic disorders in the US population ranged from 0.25% to 0.64%. Additionally, in January 2024, the British Columbia Schizophrenia Society, a nonprofit organization based in Canada, stated that schizophrenia is a leading cause of hospitalization for mental illnesses, accounting for 19.9% of general hospital admissions and 30.9% of psychiatric hospital stays. As a result, the increasing number of schizophrenia cases will fuel the growth of the schizophrenia drugs market.

Leading companies in the schizophrenia drugs market are focused on developing advanced treatments, such as oral medications for schizophrenia, to improve patient care and treatment outcomes. Oral medications for schizophrenia are taken by mouth to manage the symptoms of the disorder, typically involving antipsychotics that help stabilize mood, thoughts, and perceptions. For example, in September 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Cobenfy, an innovative oral medication for treating schizophrenia in adults. This groundbreaking drug combines xanomeline and trospium chloride, offering a new approach compared to traditional antipsychotics by targeting cholinergic receptors rather than dopamine receptors. This unique mechanism has the potential to alleviate symptoms such as delusions and disorganized thinking while minimizing the common side effects associated with older antipsychotic medications, making Cobenfy a promising alternative in schizophrenia treatment.

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. This acquisition is expected to enhance Bristol Myers Squibb's neuroscience portfolio by adding KarXT, a new antipsychotic, and expanding its pipeline with potential treatments for schizophrenia, Alzheimer's disease, and other mental health disorders. Karuna Therapeutics, a US-based biopharmaceutical company, specializes in producing drugs for schizophrenia.

Major players in the schizophrenia drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co., Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., Sun Pharmaceutical Industries Ltd., AbbVie Inc., H. Lundbeck A/S, Cipla Ltd., Lupin Limited, Alkermes plc, Vanda Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Mylan NV, Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Holdings Inc., Lifegenix, and Flagship Biotech International Pvt. Ltd.

North America was the largest region in the schizophrenia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in schizophrenia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the schizophrenia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The schizophrenia drugs market consists of sales of transdermal patches, liquid formulations, and adjunctive therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Schizophrenia Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on schizophrenia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for schizophrenia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The schizophrenia drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutic Class: Second Generation; Third Generation; Other Therapeutic Classes
• 2) By Treatment: Oral; Injectable
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Second Generation: Risperidone; Olanzapine; Quetiapine; Aripiprazole; Paliperidone; Ziprasidone; Others
• 2) By Third Generation: Brexpiprazole; Cariprazine; Others
• 3) By Other Therapeutic Classes: First-Generation Antipsychotics; Combination Therapies; Others
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co.; Novartis AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Schizophrenia Drugs Market Characteristics

3. Schizophrenia Drugs Market Trends And Strategies

4. Schizophrenia Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Schizophrenia Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Schizophrenia Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Schizophrenia Drugs Market Growth Rate Analysis
• 5.4. Global Schizophrenia Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Schizophrenia Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Schizophrenia Drugs Total Addressable Market (TAM)

6. Schizophrenia Drugs Market Segmentation

• 6.1. Global Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Second Generation
• Third Generation
• Other Therapeutic Classes
• 6.2. Global Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Schizophrenia Drugs Market, Sub-Segmentation Of Second Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Risperidone
• Olanzapine
• Quetiapine
• Aripiprazole
• Paliperidone
• Ziprasidone
• Others
• 6.5. Global Schizophrenia Drugs Market, Sub-Segmentation Of Third Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brexpiprazole
• Cariprazine
• Others
• 6.6. Global Schizophrenia Drugs Market, Sub-Segmentation Of Other Therapeutic Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Generation Antipsychotics
• Combination Therapies
• Others

7. Schizophrenia Drugs Market Regional And Country Analysis

• 7.1. Global Schizophrenia Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Schizophrenia Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Schizophrenia Drugs Market

• 8.1. Asia-Pacific Schizophrenia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Schizophrenia Drugs Market

• 9.1. China Schizophrenia Drugs Market Overview
• 9.2. China Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Schizophrenia Drugs Market

• 10.1. India Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Schizophrenia Drugs Market

• 11.1. Japan Schizophrenia Drugs Market Overview
• 11.2. Japan Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Schizophrenia Drugs Market

• 12.1. Australia Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Schizophrenia Drugs Market

• 13.1. Indonesia Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Schizophrenia Drugs Market

• 14.1. South Korea Schizophrenia Drugs Market Overview
• 14.2. South Korea Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Schizophrenia Drugs Market

• 15.1. Western Europe Schizophrenia Drugs Market Overview
• 15.2. Western Europe Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Schizophrenia Drugs Market

• 16.1. UK Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Schizophrenia Drugs Market

• 17.1. Germany Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Schizophrenia Drugs Market

• 18.1. France Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Schizophrenia Drugs Market

• 19.1. Italy Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Schizophrenia Drugs Market

• 20.1. Spain Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Schizophrenia Drugs Market

• 21.1. Eastern Europe Schizophrenia Drugs Market Overview
• 21.2. Eastern Europe Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Schizophrenia Drugs Market

• 22.1. Russia Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Schizophrenia Drugs Market

• 23.1. North America Schizophrenia Drugs Market Overview
• 23.2. North America Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Schizophrenia Drugs Market

• 24.1. USA Schizophrenia Drugs Market Overview
• 24.2. USA Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Schizophrenia Drugs Market

• 25.1. Canada Schizophrenia Drugs Market Overview
• 25.2. Canada Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Schizophrenia Drugs Market

• 26.1. South America Schizophrenia Drugs Market Overview
• 26.2. South America Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Schizophrenia Drugs Market

• 27.1. Brazil Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Schizophrenia Drugs Market

• 28.1. Middle East Schizophrenia Drugs Market Overview
• 28.2. Middle East Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Schizophrenia Drugs Market

• 29.1. Africa Schizophrenia Drugs Market Overview
• 29.2. Africa Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Schizophrenia Drugs Market Competitive Landscape And Company Profiles

• 30.1. Schizophrenia Drugs Market Competitive Landscape
• 30.2. Schizophrenia Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Schizophrenia Drugs Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb
• 31.2. AstraZeneca PLC
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. F. Hoffmann-La Roche Ltd.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. UCB S.A.
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. AbbVie Inc.
• 31.10. H. Lundbeck A/S
• 31.11. Cipla Ltd.
• 31.12. Lupin Limited
• 31.13. Alkermes plc
• 31.14. Vanda Pharmaceuticals Inc.
• 31.15. Sumitomo Pharma Co. Ltd.

32. Global Schizophrenia Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Schizophrenia Drugs Market

34. Recent Developments In The Schizophrenia Drugs Market

35. Schizophrenia Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Schizophrenia Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Schizophrenia Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Schizophrenia Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer